DeepMed Research

UNIVERSITY OF CALIFORNIA, DAVIS

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private, Subsidiary

Established: 1905-01-01

Employees: 10K

Market Cap: -

Website: http://www.ucdavis.edu

Clinical Trials

Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer

Phase 1

Completed

Conditions: Recurrent Bladder Carcinoma
Stage IV Bladder Urothelial Carcinoma
Stage IV Urethral Cancer
Urethral Urothelial Carcinoma
Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter
Regional Urothelial Carcinoma of the Renal Pelvis and Ureter
Stage III Bladder Urothelial Carcinoma
Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter
Stage III Urethral Cancer

Interventions: Drug: Pembrolizumab
Drug: Docetaxel
Drug: Gemcitabine Hydrochloride

First Posted Date: 2015-05-07

Last Posted Date: 2022-10-18

Lead Sponsor: University of California, Davis

Target Recruit Count: 32

Registration Number: NCT02437370

Locations: 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

Trial of Simvastatin for the Treatment of Severe Asthma

Phase 2

Withdrawn

Conditions: Severe Asthma

Interventions: Other: Placebo
Drug: Simvastatin

First Posted Date: 2015-05-05

Last Posted Date: 2017-09-26

Lead Sponsor: University of California, Davis

Registration Number: NCT02433535

Locations: 🇺🇸
CTSC Clinical Research Center, Sacramento, California, United States

Lao Zinc Study: Effects of Two Forms of Daily Preventive Zinc Versus Therapeutic Zinc Supplementation

Not Applicable

Completed

Conditions: Diarrhea

Interventions: Dietary Supplement: therapeutic placebo supplement
Dietary Supplement: preventive zinc supplement
Dietary Supplement: MNP
Dietary Supplement: therapeutic zinc supplement
Dietary Supplement: placebo powder
Dietary Supplement: preventive placebo supplement

First Posted Date: 2015-04-29

Last Posted Date: 2022-01-20

Lead Sponsor: University of California, Davis

Target Recruit Count: 3433

Registration Number: NCT02428647

Locations: 🇱🇦
Lao Tropical and Public Health Institute, Vientiane, Lao People's Democratic Republic

Visual Interpretation of Neonatal Growth Charts

Completed

Conditions: Growth Acceleration
Growth Retardation

First Posted Date: 2015-03-31

Last Posted Date: 2017-06-21

Lead Sponsor: University of California, Davis

Target Recruit Count: 50

Registration Number: NCT02403739

Locations: 🇺🇸
UC Davis, Sacramento, California, United States

Dermal Suturing Only Versus Layered Cutaneous Closure

Not Applicable

Completed

Conditions: Wound Closure Techniques

Interventions: Procedure: Dermal Suturing Only Wound Closure
Procedure: Layered Cutaneous Wound Closure

First Posted Date: 2015-03-09

Last Posted Date: 2017-07-18

Lead Sponsor: University of California, Davis

Target Recruit Count: 50

Registration Number: NCT02383186

NSAIDS Versus Opioids in Acute SER II Ankle Fractures

Early Phase 1

Completed

Conditions: Ankle Fracture

Interventions: Drug: Acetaminophen/hydrocodone
Drug: Ibuprofen

First Posted Date: 2015-02-26

Last Posted Date: 2017-07-14

Lead Sponsor: University of California, Davis

Target Recruit Count: 1

Registration Number: NCT02373254

Locations: 🇺🇸
University of California Davis, Sacramento, California, United States

Impact of Individualized Radiotherapy Plan Review in Patients Receiving Adjuvant Radiotherapy for Breast Cancer

Completed

Conditions: Breast Cancer

First Posted Date: 2015-02-19

Last Posted Date: 2020-10-28

Lead Sponsor: University of California, Davis

Target Recruit Count: 72

Registration Number: NCT02366806

Locations: 🇺🇸
UC Davis Medical Center, Sacramento, California, United States

Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib

Phase 1

Completed

Conditions: Recurrent Non-Small Cell Lung Carcinoma
Stage IIIB Non-Small Cell Lung Cancer
Stage IV Non-Small Cell Lung Cancer
Stage IIIA Non-Small Cell Lung Cancer

Interventions: Drug: Afatinib Dimaleate
Biological: Pembrolizumab

First Posted Date: 2015-02-18

Last Posted Date: 2024-10-16

Lead Sponsor: Jonathan Riess

Target Recruit Count: 11

Registration Number: NCT02364609

Locations: 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse

Phase 2

Withdrawn

Conditions: Recurrent Adult Brain Neoplasm
Adult Brain Glioblastoma

Interventions: Procedure: Electric Field Therapy
Biological: Bevacizumab
Drug: Carmustine
Other: Quality-of-Life Assessment

First Posted Date: 2015-01-28

Last Posted Date: 2018-01-09

Lead Sponsor: University of California, Davis

Registration Number: NCT02348255

Locations: 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸
Piedmont Hospital, Atlanta, Georgia, United States

Enzalutamide and Metformin Hydrochloride in Treating Patients With Hormone-Resistant Prostate Cancer

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Drug: Enzalutamide
Drug: Metformin Hydrochloride

First Posted Date: 2015-01-15

Last Posted Date: 2025-05-01

Lead Sponsor: University of California, Davis

Target Recruit Count: 25

Registration Number: NCT02339168

Locations: 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy